GT Biopharma (GTBP) Stock Price, News & Analysis

Company Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Key Stats

• Today's Range: $2.23 to $2.27
• 50-Day Range: $2.15 to $2.56
• 52-Week Range: $1.72 to $10.66
• Volume: 5,197 shs
• Average Volume: 582,559 shs
• Market Capitalization: $5.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Strong Buy

GT Biopharma Stock Analysis - MarketRank™

GT Biopharma scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

GT Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GT Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GT Biopharma is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GT Biopharma is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GT Biopharma has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.74% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GT Biopharma has recently decreased by 23.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GT Biopharma does not currently pay a dividend.

Dividend Growth

GT Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.74% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GT Biopharma has recently decreased by 23.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.50

News Sentiment

GT Biopharma has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for GT Biopharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GT Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.90% of the stock of GT Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.15% of the stock of GT Biopharma is held by institutions.

GTBP Stock Analysis - Frequently Asked Questions

How have GTBP shares performed this year?

GT Biopharma's stock was trading at $3.05 at the start of the year. Since then, GTBP shares have decreased by 26.9% and is now trading at $2.23.
View the best growth stocks for 2025 here.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (NASDAQ:GTBP) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12.

When did GT Biopharma's stock split?

GT Biopharma shares reverse split before market open on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are GT Biopharma's major shareholders?

GT Biopharma's top institutional shareholders include DekaBank Deutsche Girozentrale. Insiders that own company stock include Michael Martin Breen and Manu Ohri.
View institutional ownership trends.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 5/18/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GTBP
• Previous Symbol: OTCMKTS:OXISD
• CIK: 109657
• Web: www.gtbiopharma.com
• Phone: (415) 919-4040
• Fax: N/A
• Employees: 8
• Year Founded: 1965

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +393.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,600,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -257.47%
• Return on Assets: -131.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.45
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.42 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 2,536,000
• Free Float: 1,990,000
• Market Cap: $5.66 million
• Optionable: No Data
• Beta: 1.48